Heron Therapeutics Announces U.S. Commercial Launch of APONVIE™
Tuesday, March 07, 2023
Heron Therapeutics announced APONVIE (aprepitant) injectable emulsion, is now commercially available for intravenous (IV) use in adults for the prevention of PONV.
The launch of APONVIE will now allow providers to prevent PONV without the limitations of the current oral route of administration.
Delivered via a single IV injection, APONVIE reaches drug levels associated with ≥97% receptor occupancy in the brain within five minutes and maintains therapeutic plasma concentrations for at least 48 hours. This ready-to-use, easy to administer, innovative IV formulation ensures rapid and consistent exposure in patients undergoing surgery. Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron.
There are approximately 36 million procedures in the U.S. each year involving patients with high to moderate risk for PONV, the patients benefit most from APONVIE. This launch supports the ongoing commitment to deliver innovative solutions that improve the postoperative experience by addressing the two most common concerns after surgery, postoperative pain with ZYNRELEF® and postoperative nausea and vomiting with APONVIE.
